Table 1 Baseline characteristics of participants
From: Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis
Variables | Control group (n = 90,313) | Bronchiectasis group (n = 18,134) | P-value |
|---|---|---|---|
Age, years | 51.5 ± 11.9 | 59.6 ± 11.7 | < 0.001 |
Male | 52,631 (58.3) | 8654 (47.7) | < 0.001 |
BMI, kg/m2 | 23.8 ± 3.1 | 22.7 ± 3.3 | < 0.001 |
Smoking |  |  | < 0.001 |
 Never | 15,931 (17.6) | 5020 (27.7) |  |
 Ever | 10,264 (11.4) | 2859 (15.8) |  |
Comorbidities | |||
 Hypertension | 9496 (10.5) | 2194 (12.1) | < 0.001 |
 Diabetes | 6249 (6.9) | 1552 (8.6) | < 0.001 |
 Dyslipidaemia | 13,707 (15.2) | 2269 (12.5) | < 0.001 |
 COPD | 1882 (2.1) | 16,498 (9.0) | < 0.001 |
 Asthma | 2372 (2.6) | 1445 (8.0) | < 0.001 |
Baseline PFT, n | 60,854 | 10,279 | Â |
 FEV1 (L) | 3.1 ± 0.7 | 2.3 ± 0.8 | < 0.001 |
 FEV1 (% predicted) | 98 ± 11 | 92 ± 16 | < 0.001 |
 FVC (L) | 3.8 ± 0.9 | 3.1 ± 0.9 | < 0.001 |
 FVC (% predicted) | 98 ± 11 | 92 ± 16 | < 0.001 |
 FEV1: FVC ratio (%) | 81 ± 5 | 74 ± 12 | < 0.001 |